Michelle Fodor
Novartis (United States)(US)
Publications by Year
Research Areas
Protein Tyrosine Phosphatases, Galectins and Cancer Biology, Bioactive Compounds and Antitumor Agents, Atherosclerosis and Cardiovascular Diseases, PI3K/AKT/mTOR signaling in cancer
Most-Cited Works
- → Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases(2016)909 cited
- → Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor(2016)286 cited
- → Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer(2020)210 cited
- → Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition(2018)163 cited
- → Dual Allosteric Inhibition of SHP2 Phosphatase(2018)127 cited
- → 6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors(2019)86 cited
- → Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors(2019)80 cited
- → ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor(2016)73 cited
- → Structural and Functional Consequences of Three Cancer-Associated Mutations of the Oncogenic Phosphatase SHP2(2016)69 cited
- → Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2(2017)52 cited